Skip to content
Try Mental Wellness – Lifestyle
Author:
XORTX Therapeutics Inc.
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
October 8, 2026
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
September 18, 2026
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
September 10, 2026
XORTX Announces Termination and Postponement of Investor Relations Program
August 28, 2026
XORTX Announces Director Resignation
July 31, 2026
XORTX Appoints New Director
July 29, 2026
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
June 15, 2026
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
June 12, 2026
XORTX Announces Closing of US$5 Million Public Offering
May 19, 2026
XORTX Announces US$5 Million Public Offering
May 14, 2026
1
2
Next Page
→